APA
Li L., Zhuang Q., Cao Z., Yin R., Zhu Y., Zhu L., Xie X., Zhang Y., Li L., Wu Q., Zheng J., Zhou Q., Li X., Wu L., Feng Y. & Wang C. (2018). Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial. : Oncology letters.
Chicago
Li Li, Zhuang Qingqing, Cao Zeyi, Yin Rutie, Zhu Yaping, Zhu Lirong, Xie Xing, Zhang Youzhong, Li Li, Wu Qiang, Zheng Jianhua, Zhou Qi, Li Xiaoping, Wu Lingying, Feng Youji and Wang Changyu. 2018. Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial. : Oncology letters.
Harvard
Li L., Zhuang Q., Cao Z., Yin R., Zhu Y., Zhu L., Xie X., Zhang Y., Li L., Wu Q., Zheng J., Zhou Q., Li X., Wu L., Feng Y. and Wang C. (2018). Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial. : Oncology letters.
MLA
Li Li, Zhuang Qingqing, Cao Zeyi, Yin Rutie, Zhu Yaping, Zhu Lirong, Xie Xing, Zhang Youzhong, Li Li, Wu Qiang, Zheng Jianhua, Zhou Qi, Li Xiaoping, Wu Lingying, Feng Youji and Wang Changyu. Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial. : Oncology letters. 2018.